Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1

被引:181
作者
Hanai, J
Dhanabal, M
Karumanchi, SA
Albanese, C
Waterman, M
Chan, B
Ramchandran, R
Pestell, R
Sukhatme, VP
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Nephrol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Study Tumor Microenvironm, Boston, MA 02215 USA
[4] Albert Einstein Coll Med, Dept Dev & Mol Biol & Med, Bronx, NY 10462 USA
关键词
D O I
10.1074/jbc.M112274200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endostatin, a type XVIII collagen fragment, is a potent antiangiogenic molecule that inhibits endothelial cell migration, promotes apoptosis, and induces cell cycle arrest in vitro. We have investigated the mechanism by which endostatin causes G, arrest in endothelial cells. Endostatin decreased the hyperphosphorylated retinoblastoma gene product and down-regulated cyclin D1 mRNA and protein. Importantly, endostatin was unable to arrest cyclin D1 overexpressing endothelial cells, suggesting that cyclin D1 is a critical target for endostatin action. Next, we analyzed cyclin D1 promoter activity in endothelial cells and found that endostatin down-regulated the cyclin D1 promoter. Using a series of deletion and mutant promoter constructs, we identified the LEF1 site in the cyclin D1 promoter as essential for the inhibitory effect of endostatin. Finally, we showed that endostatin can repress cyclin D1 promoter activity in cells over-expressing beta-catenin but not in cells over-expressing a transcriptional activator that functions through the LEF1 site and is insensitive to beta-catenin. Collectively, our data pointed to a role for cyclin D1, and in particular, transcription through the LEF1 site as critical for endostatin action in vitro and suggest that beta-catenin is a target for endostatin.
引用
收藏
页码:16464 / 16469
页数:6
相关论文
共 29 条
  • [1] Arber N, 1997, CANCER RES, V57, P1569
  • [2] Mammalian G1- and S-phase checkpoints in response to DNA damage
    Bartek, J
    Lukas, J
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2001, 13 (06) : 738 - 747
  • [3] DAKSIS JI, 1994, ONCOGENE, V9, P3635
  • [4] Cloning, expression, and in vitro activity of human endostatin
    Dhanabal, M
    Volk, R
    Ramchandran, R
    Simons, M
    Sukhatme, VP
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 258 (02) : 345 - 352
  • [5] Dhanabal M, 1999, CANCER RES, V59, P189
  • [6] Endostatin induces endothelial cell apoptosis
    Dhanabal, M
    Ramchandran, R
    Waterman, MJF
    Lu, H
    Knebelmann, B
    Segal, M
    Sukhatme, VP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (17) : 11721 - 11726
  • [7] Identification of c-MYC as a target of the APC pathway
    He, TC
    Sparks, AB
    Rago, C
    Hermeking, H
    Zawel, L
    da Costa, LT
    Morin, PJ
    Vogelstein, B
    Kinzler, KW
    [J]. SCIENCE, 1998, 281 (5382) : 1509 - 1512
  • [8] Cell surface glypicans are low-affinity endostatin receptors
    Karumanchi, SA
    Jha, V
    Ramchandran, R
    Karihaloo, A
    Tsiokas, L
    Chan, BD
    Dhanabal, M
    Hanai, J
    Venkataraman, G
    Shriver, Z
    Keiser, N
    Kalluri, R
    Zeng, HY
    Mukhopadhyay, D
    Chen, RL
    Lander, AD
    Hagihara, K
    Yamaguchi, Y
    Sasisekharan, R
    Cantley, L
    Sukhatme, VP
    [J]. MOLECULAR CELL, 2001, 7 (04) : 811 - 822
  • [9] Kornmann M, 1999, CANCER RES, V59, P3505
  • [10] Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum
    Kornmann, M
    Arber, N
    Korc, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) : 344 - 352